Towa Pharmaceutical Co., Ltd. (OTCMKTS:TWAPF) Short Interest Update

Towa Pharmaceutical Co., Ltd. (OTCMKTS:TWAPF) was the target of a large increase in short interest in May. As of May 29th, there was short interest totaling 33,275 shares, an increase of 114.3% from the May 14th total of 15,525 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is presently ? days.

Analyst Ratings Changes

Separately, Morgan Stanley raised shares of Towa Pharmaceutical to an “overweight” rating in a research note on Friday. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat, Towa Pharmaceutical currently has a consensus rating of “Buy”.

Towa Pharmaceutical Price Performance

Shares of TWAPF opened at $25.33 on Friday. Towa Pharmaceutical has a twelve month low of $16.83 and a twelve month high of $25.33. The company has a 50 day moving average of $25.33 and a 200-day moving average of $25.33.

Towa Pharmaceutical Company Profile

Towa Pharmaceutical Co, Ltd. (OTCMKTS:TWAPF) is a Japan-based healthcare company primarily engaged in the research, development, manufacturing and sale of pharmaceutical products. The company’s product portfolio spans active pharmaceutical ingredients (APIs), finished dosage forms such as tablets and capsules, and over-the-counter (OTC) preparations. Towa Pharmaceutical serves both prescription and consumer healthcare markets, offering formulations that address chronic conditions, lifestyle-related illnesses and general wellness.

In addition to its in-house product lines, Towa Pharmaceutical provides contract manufacturing and development services to domestic and international partners.